President Donald Trump signed an executive order aimed at significantly speeding up the FDA review process for psychedelic drugs that show promise in treating post-traumatic stress disorder (PTSD) and traumatic brain injuries, particularly for military veterans. During a press conference in the Oval Office, Trump emphasized the critical need for new treatments for veterans, highlighting the ongoing suicide epidemic within this population as a national tragedy.
Trump noted that since 9/11, significantly more veterans have died by suicide than in combat. To underscore the potential of these therapies, Trump referenced a 2024 study from Stanford University involving 30 special operations veterans who had experienced traumatic brain injuries. After undergoing treatment with ibogaine, these veterans reportedly saw an 80% to 90% decrease in symptoms of depression and anxiety within a single month.
Despite ibogaine and other psychedelics being classified as highly restricted illegal drugs under federal law, the Trump administration is actively working to reduce restrictions and encourage medical research. The executive order specifically directs the Food and Drug Administration to prioritize and expedite applications for treatments that have demonstrated early success in clinical trials for PTSD, traumatic brain injury, depression, anxiety, and other mental health challenges. The signing ceremony was attended by key health officials and Marcus Luttrell, a former Navy SEAL whose experiences were depicted in the film Lone Survivor. Luttrell expressed his belief that the order would “save a lot of lives through it. It absolutely changed my life for the better.” However, critics have voiced concerns that accelerating the FDA’s approval process could compromise safety and oversight.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/trump-administration-accelerates-review-of-psychedelic-82393480